Disc Medicine reports positive updated Phase 2 BEACON data for bitopertin; PPIX drops >40%, sunlight tolerance improves

Disc Medicine, Inc.

PPIX levels reduced >40% (p<0.001) from baseline; sustained and dose-dependent in 22 EPP patients.
Time to prodrome improved >3x; proportion of days without symptoms rose to 78% vs 33% baseline.
Mean cumulative time in light over 6 months: 222.6 hours (>3x historical control) on precedented pivotal endpoint.
Bitopertin well-tolerated with no serious AEs; stable mean hemoglobin, no anemia events reported.
Initial positive Phase 1b data for DISC-0974 in myelofibrosis showed hemoglobin improvements and reduced transfusions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.